Logo

Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy

Share this
Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy

Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy

Shots:

  • The approval is based on the CodeBreaK 100 trial evaluating the efficacy & tolerability of Lumakras (960mg- qd) in 124 patients with KRAS G12C mutation-positive NSCLC whose disease had progressed after prior treatment with immunotherapy or CT
  • Results: ORR (36%); DCR (81%); mDoR (10 mos.); durable response with a positive benefit-risk profile- 9% showed permanent discontinuation due to AEs
  • The company is conducting biomarker testing & a patient support program for NSCLC. The therapy is also being studied in multiple other solid tumors

  Ref: PRNewswire | Image: BioSpace

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions